Catalyst Pharmaceuticals, Inc. (FRA:CN2)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.37B +48.6% |
| Revenue (ttm) | 517.74M +11.7% |
| Net Income | 191.95M +12.1% |
| EPS | 1.50 +10.3% |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 27.30 |
| Previous Close | 26.60 |
| Day's Range | 27.30 - 27.30 |
| 52-Week Range | 16.15 - 27.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste... [Read more]
Financial Performance
In 2025, Catalyst Pharmaceuticals's revenue was $588.99 million, an increase of 19.78% compared to the previous year's $491.73 million. Earnings were $214.33 million, an increase of 30.78%.
Financial numbers in USD Financial StatementsNews
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership o...
Catalyst Pharmaceuticals Transcript: EGM 2026
Stockholders voted on a merger with Angelini Pharma S.p.A., approving the merger proposal but not the advisory compensation proposal. The adjournment proposal was not needed as the merger passed.
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate V...
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on June 30, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 12, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funde...
Catalyst Pharmaceuticals Quarterly report: Q1 2026
Catalyst Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 11, 2026.
Catalyst Pharmaceuticals Earnings release: Q1 2026
Catalyst Pharmaceuticals released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, deve...
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharmaceuticals Proxy statement: Proxy filing
Catalyst Pharmaceuticals filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
The move marks Italy's Angelini Pharma's entry into the U.S. market.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
Italy's Angelini Pharma said on Thursday it has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion.
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration ...
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET
See How Institutions Boost Catalyst Shares
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022's first outlier institutional inflow signal.
Catalyst Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
The company reported strong 2025 results with 20% revenue growth and expects continued momentum in 2026, driven by Firdapse and Agamree. Firdapse benefits from new guidelines and expanded oncology focus, while Agamree's adoption is supported by promising clinical data and broad market uptake. Cash reserves and a share repurchase program provide flexibility for acquisitions and shareholder returns.
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and...
Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 revenues of $589M (up 19.8% YoY) driven by Firdapse and AGAMREE, with strong net income growth and robust cash position. 2026 guidance projects continued double-digit growth, supported by expanded patient identification and market penetration initiatives.
Catalyst Pharmaceuticals Earnings release: Q4 2025
Catalyst Pharmaceuticals released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.